Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 348

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity

Open access
Moral, John Alec, Leung, Joanne, Rojas, Luis A., Ruan, Jennifer, Zhao, Julia, Sethna, Zachary, Ramnarain, Anita, Gasmi, Billel, Gururajan, Murali, Redmond, David, Askan, Gokce, Bhanot, Umesh, Elyada, Ela, Park, Youngkyu, Tuveson, David A., Gönen, Mithat, Leach, Steven D., Wolchok, Jedd D., DeMatteo, Ronald P., Merghoub, Taha, Balachandran, Vinod P.·2020·Nature

Abstract

Group 2 innate lymphoid cells (ILC2s) regulate inflammation and immunity in mammalian tissues1,2. Although ILC2s are found in cancers of these tissues3, their roles in cancer immunity and immunotherapy are unclear. Here we show that ILC2s infiltrate pancreatic ductal adenocarcinomas (PDACs) to activate tissue-specific tumour immunity. Interleukin-33 (IL33) activates tumour ILC2s (TILC2s) and CD8+ T cells in orthotopic pancreatic tumours but not heterotopic skin tumours in mice to restrict pancreas-specific tumour growth. Resting and activated TILC2s express the inhibitory checkpoint receptor PD-1. Antibody-mediated PD-1 blockade relieves ILC2 cell-intrinsic PD-1 inhibition to expand TILC2s, augment anti-tumour immunity, and enhance tumour control, identifying activated TILC2s as targets of anti-PD-1 immunotherapy. Finally, both PD-1+ TILC2s and PD-1+ T cells are present in most human PDACs. Our results identify ILC2s as anti-cancer immune cells for PDAC immunotherapy. More broadly, ILC2s emerge as tissue-specific enhancers of cancer immunity that amplify the efficacy of anti-PD-1 immunotherapy. As ILC2s and T cells co-exist in human cancers and share stimulatory and inhibitory pathways, immunotherapeutic strategies to collectively target anti-cancer ILC2s and T cells may be broadly applicable. Tumour-infiltrating group 2 innate lymphoid cells prime CD8+ T cells and amplify the anti-tumour effects of PD-1 blockade in pancreatic ductal adenocarcinoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-020-2015-4

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 348

Metadata

Authors
Moral, J. A., Leung, J., Rojas, L. A., Ruan, J., Zhao, J., Sethna, Z., Ramnarain, A., Gasmi, B., Gururajan, M., Redmond, D., Askan, G., Bhanot, U., Elyada, E., Park, Y., Tuveson, D. A., Gönen, M., Leach, S. D., Wolchok, J. D., DeMatteo, R. P., Merghoub, T., & Balachandran, V. P.
Venue
Nature
Published
2020-02-19
Volume
579
Issue
7797
Pages
130-135
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W3008176582
Cited by
348
References
33
FWCI
16.33
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. https://app.cochat.ai/papers/10.1038/s41586-020-2015-4
The paper
Moral, J. A., Leung, J., Rojas, L. A., Ruan, J., Zhao, J., Sethna, Z., Ramnarain, A., Gasmi, B., Gururajan, M., Redmond, D., Askan, G., Bhanot, U., Elyada, E., Park, Y., Tuveson, D. A., Gönen, M., Leach, S. D., Wolchok, J. D., DeMatteo, R. P., . . . Balachandran, V. P. (2020). ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature. https://doi.org/10.1038/s41586-020-2015-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.